Asthma Diagnosis and Treatment

Diagnosis and Assessment

• The American Thoracic Society recommends that asthma diagnosis be confirmed with spirometry demonstrating variable airflow obstruction through a bronchodilator reversibility test, with an improvement of ≥12% and ≥200 mL in FEV1 1.
• The National Heart, Lung, and Blood Institute suggests that peak expiratory flow (PEF) measurements be used to establish baseline values and evaluate daily variability, with variability >20% suggesting asthma 1.
• The American Academy of Allergy, Asthma, and Immunology recommends documenting key symptoms, including frequency of daytime symptoms, nighttime awakenings, activity limitation, and use of rescue medications 2, 1.
• The American College of Allergy, Asthma, and Immunology suggests that allergy tests be performed in patients with persistent asthma who require daily medication, using skin or in vitro tests for perennial allergens 3, 4.

Classification of Severity and Control

• The Global Initiative for Asthma recommends classifying asthma severity into two domains: current impairment and future risk, using criteria such as symptoms, nighttime awakenings, and lung function 2, 5.
• The National Asthma Education and Prevention Program suggests classifying asthma control into three categories: well-controlled, not well-controlled, and very poorly controlled, based on symptoms, nighttime awakenings, and lung function 6, 7.

Pharmacological Treatment

• The American Thoracic Society recommends that inhaled corticosteroids (ICS) be used as the preferred long-term control therapy for persistent asthma, due to their anti-inflammatory effects 3, 4, 1.
• The Global Initiative for Asthma suggests using a stepwise approach to adjust treatment, with the goal of achieving and maintaining control, and reducing treatment when possible 2, 8.

Monitoring and Adjusting Treatment

• The American Academy of Allergy, Asthma, and Immunology recommends regular follow-up visits to assess asthma control, inhaler technique, and patient concerns, and to adjust treatment as needed 7, 1.
• The National Heart, Lung, and Blood Institute suggests using validated tools, such as the Asthma Control Test (ACT) or Asthma Control Questionnaire (ACQ), to assess asthma control 8, 1.

Patient Education and Self-Management

• The American Thoracic Society recommends developing a written action plan with patients, including instructions for daily monitoring, recognizing inadequate control, and adjusting medications, to improve self-management and reduce urgent visits and hospitalizations 2, 4.
• The American Academy of Allergy, Asthma, and Immunology suggests evaluating and correcting inhaler technique at each visit, as inadequate technique is a common cause of poor control 7, 1.

Initial Treatment Approach for Confirmed Asthma

Severity Assessment and Initial Pharmacological Treatment

• The American Academy of Allergy, Asthma, and Immunology recommends initiating treatment with an inhaled corticosteroid (ICS) as the preferred first-line long-term controller therapy, combined with a short-acting beta-agonist (SABA) for symptom relief, using a stepwise approach based on initial severity assessment 9
• Assess key parameters, including frequency of daytime symptoms, nighttime awakenings, activity limitation, rescue medication use, and lung function (FEV1 or peak expiratory flow), to determine the appropriate initial step 9, 10
• Identify triggers and comorbidities, such as exposure to allergens/irritants at home or work, and conditions like rhinitis, GERD, or obesity that may impede control 9, 11

Initial Pharmacological Treatment by Severity

• For mild persistent asthma, daily low-dose ICS is the cornerstone of treatment, with the addition of SABA for quick relief of breakthrough symptoms 9, 10
• For moderate persistent asthma, medium-dose ICS or low-dose ICS combined with a long-acting beta-agonist (LABA) is recommended 9, 11
• For severe persistent asthma, high-dose ICS-LABA combination is the foundation therapy, with consideration of adding a long-acting muscarinic antagonist (triple therapy) to improve symptoms, lung function, and reduce exacerbations 9, 11

Essential Non-Pharmacological Components

• Teach and verify proper inhaler technique at every visit, as inadequate technique is a common cause of poor control 11
• Educate patients on the difference between long-term controller medications (taken daily) and quick-relief medications (used as needed) 11
• Identify and reduce exposure to specific triggers, using skin testing or specific IgE measurements to identify relevant allergens in patients with persistent asthma 11, 12, 13

Monitoring Parameters and Goals of Initial Treatment

• Instruct patients to monitor asthma control ongoing, either through symptom monitoring or peak flow monitoring, with evidence suggesting similar benefits 9, 10
• The treatment aims to achieve minimal chronic symptoms, infrequent use of rescue bronchodilators (≤2 days/week), no limitations on activities, normal or near-normal pulmonary function (PEF ≥80% predicted), and minimal exacerbations and prevention of ED visits or hospitalizations 9, 10, 12, 13

Asthma Management Guidelines

Initial Assessment and Diagnosis

• The American College of Allergy, Asthma, and Immunology recommends assessing environmental exposures, such as tobacco smoke, mold, house dust mite, cockroach, and animal dander, to identify potential asthma triggers 14
• Repeat spirometry at initial assessment, after treatment initiation, during periods of progressive loss of control, and at least every 1-2 years to monitor asthma control 15, 16
• Document nighttime awakenings per week, activity limitations, and days of restricted physical activity to assess asthma severity 15, 16
• Quantify rescue medication use, such as short-acting beta-agonist puffs per day, to monitor asthma control 15, 16
• Note any unscheduled visits, ED presentations, or hospitalizations to assess asthma severity 15, 16

Classification and Treatment Selection

• The American Academy of Family Physicians recommends initiating daily low-dose inhaled corticosteroids (ICS) as first-line controller therapy for mild persistent asthma 17
• For moderate persistent asthma, use medium-dose ICS or low-dose ICS combined with long-acting beta-agonist (LABA) 17
• Inhaled corticosteroids are the preferred controller medication because they improve asthma control more effectively than any other single long-term control medication when used consistently 17

Patient Education and Self-Management

• Provide written asthma action plans to all patients, including instructions for daily management, signs of worsening asthma, and medication adjustments 14, 15, 16
• Teach proper inhaler technique and verify technique at every visit 14
• Educate patients on recognizing symptoms, adjusting medications, and seeking medical care when necessary 14, 18
• Use varied educational strategies for different health literacy levels, including individual instruction, group programs, and written materials 14, 18

Monitoring and Adjusting Treatment

• Review patient concerns and difficulties adhering to the action plan at every visit 14
• Assess asthma control at each visit using validated tools, such as the Asthma Control Test (ACT) or Asthma Control Questionnaire (ACQ) 14
• Adjust treatment based on control, using a stepwise approach to step up or step down therapy as needed 17
• Increasing use of short-acting beta-agonists (>2 days/week or >2 nights/month) indicates inadequate control and need to initiate or intensify anti-inflammatory therapy 17

Environmental Control Measures

• Eliminate tobacco smoke exposure and reduce allergen exposure based on specific sensitivities identified through testing 14
• Address environmental factors that cause exacerbations, such as mold, house dust mite, cockroach, and animal dander 14
• Substantially reducing exposure to these factors may reduce inflammation, symptoms, and medication needs 14

Special Considerations for Disparities

• Address barriers to guideline-based care, including cultural and ethnic factors, language barriers, health literacy, and socioeconomic circumstances 14, 16, 18
• Provide communication skills training to enhance competence in caring for multicultural populations 14
• Incorporate individualized case management by trained professionals for patients with poorly controlled asthma and recurrent ED/hospital visits 14

Asthma Management Guidelines Based on Cited Facts

Patient Education and Management

• The American Thoracic Society recommends that patients with asthma should be provided with a written asthma action plan including instructions for daily management, recognizing worsening symptoms, and medication adjustments, and should be taught to recognize when peak expiratory flow drops below 75% of personal best or predicted value, indicating need to increase treatment 19
• The Thorax journal suggests that antibiotics should not be prescribed unless bacterial infection is confirmed, as they are overused in asthma exacerbations without evidence of benefit, and sedation should never be used during acute exacerbations as it is contraindicated and dangerous, and percussive physiotherapy should not be used during acute exacerbations as it is unnecessary and unhelpful 20

Asthma Management Guidelines

Key Principles

• The American College of Allergy, Asthma, and Immunology recommends using low-dose inhaled corticosteroid-formoterol (ICS-formoterol) as needed for mild intermittent asthma, which reduces exacerbations and improves outcomes 21
• The assessment framework separates severity classification and control assessment, with severity classification used only at initial presentation to guide starting therapy, and control assessment driving all subsequent treatment adjustments 22, 23, 24

Stepwise Treatment Algorithm

• For mild intermittent asthma, the preferred treatment is as-needed low-dose ICS-formoterol, which replaces the outdated recommendation of SABA monotherapy 21
• For mild persistent asthma, the preferred treatment is daily low-dose ICS or as-needed low-dose ICS-formoterol, with low-dose ICS improving asthma control more effectively than any other single long-term controller medication (Level A evidence) 22, 23, 24
• For moderate persistent asthma, the preferred treatment is low-to-medium dose ICS-LABA combination, which demonstrates synergistic effects achieving efficacy equivalent to or better than doubling ICS dose alone 25, 22, 21

Essential Management Components

• The American Academy of Family Physicians recommends performing allergy testing for perennial indoor allergens in all patients with persistent asthma requiring daily medications, and identifying and reducing exposure to house dust mite, cockroach, cat/dog allergens, mold, and tobacco smoke in sensitized patients 25
• The American College of Allergy, Asthma, and Immunology recommends evaluating and treating conditions that worsen asthma control, including allergic rhinitis and chronic rhinosinusitis, gastroesophageal reflux disease, obesity, anxiety, and depression, and providing annual influenza vaccination for all patients with persistent asthma 25, 24

Comorbidity Management

• The American Academy of Family Physicians recommends evaluating and treating conditions that worsen asthma control, including allergic rhinitis and chronic rhinosinusitis, gastroesophageal reflux disease, obesity, anxiety, and depression 25, 24

Evidence‑Based Asthma Severity Classification and Management

1. Classification of Asthma Severity

• Severity is determined using both impairment (symptom frequency, night awakenings, reliever use, activity limitation, lung function) and risk (frequency of oral‑corticosteroid‑requiring exacerbations) domains, and the patient is assigned to the most severe category present in any single feature. 26
• Impairment criteria (American Family Physician 2009):
  
  • Daytime symptoms – ≤2 days/week = intermittent; >2 days/week but not daily = mild persistent; daily = moderate persistent; throughout the day = severe persistent.
  • Nighttime awakenings – ≤2 times/month = intermittent; 3‑4 times/month = mild persistent; >once/week but not nightly = moderate persistent; ≥7 times/week = severe persistent.
  • SABA reliever use – ≤2 days/week = intermittent; >2 days/week but not daily = mild persistent; daily = moderate persistent; several times/day = severe persistent.
  • Activity limitation – none = intermittent; minor = mild persistent; some = moderate persistent; extreme = severe persistent.
  • Lung function – FEV₁ ≥ 80 % predicted with normal FEV₁/FVC = intermittent/mild; FEV₁ 60‑80 % predicted = moderate; FEV₁ < 60 % predicted = severe persistent. 26
• Risk criteria (American Family Physician 2009):
  
  • 0‑1 oral‑corticosteroid courses per year → lower severity; ≥2 courses per year → higher severity regardless of other features. 26

2. Initial Pharmacologic Treatment by Severity

3. Ongoing Assessment of Asthma Control

• At every visit, evaluate the following well‑controlled criteria (Journal of Allergy and Clinical Immunology 2005):
• Any deviation from these criteria signals the need for treatment adjustment. 28
• Validated tools such as the Asthma Control Test (ACT) or Asthma Control Questionnaire (ACQ) should be employed to quantify control. 27
• Very poor control is indicated by PEF < 60 % predicted (or personal best). 27

4. Treatment Adjustment Algorithms

Stepping Up

• Increase therapy immediately when control is inadequate. 27
• Before stepping up, confirm:

Stepping Down

• Consider step‑down only after the patient has been well‑controlled for ≥ 3 months. 27
• Reduce to the lowest step that maintains control, monitoring closely for relapse. 27

5. Monitoring and Self‑Management

• Patients should self‑monitor using either symptom tracking or peak‑flow monitoring; both approaches provide comparable benefits. 27
• For individuals with moderate‑severe disease, a history of severe exacerbations, or poor symptom perception, peak‑flow monitoring is especially valuable.

6. Dynamic Nature of Asthma

• Asthma severity is not static; it can change over time, necessitating continuous reassessment of control status. 28

Evidence‑Based Guidelines for Diagnosis and Management of Adult Asthma

Diagnosis

• Asthma is confirmed when a patient has episodic respiratory symptoms and demonstrates reversible airflow obstruction on spirometry, defined as an increase in FEV₁ of ≥12 % and ≥200 mL after bronchodilator administration【29】.
• Baseline spirometry should show obstruction using age‑specific FEV₁/FVC thresholds: < 85 % (age 8‑19), < 80 % (20‑39), < 75 % (40‑59), < 70 % (60‑80)【30】.
• A positive bronchodilator test is defined by an FEV₁ rise of ≥12 % and ≥200 mL from baseline in adults【31】【29】.
• When initial spirometry is normal but clinical suspicion persists, bronchial provocation testing (methacholine or exercise challenge) performed by trained personnel can aid diagnosis【29】.
• A 4‑week trial of inhaled corticosteroid (ICS) therapy that yields an FEV₁ improvement >12 % and >200 mL also supports the diagnosis of asthma【31】.
• Documentation of symptom patterns—including daytime symptom frequency, nighttime awakenings, activity limitation, and rescue inhaler use—helps characterize disease severity【32】【29】【30】.
• All patients with persistent symptoms should undergo skin testing or specific IgE blood testing for perennial indoor allergens (e.g., dust mite, cockroach, pet dander, mold) to guide environmental control and identify candidates for immunotherapy【33】.
• Alternative diagnoses must be excluded before confirming asthma:
  
  • COPD is identified by a fixed obstruction with minimal reversibility, often in smokers【29】.
  • Vocal‑cord dysfunction presents with inspiratory stridor and a flattened inspiratory loop on spirometry, and does not respond to bronchodilators【29】.
  • Cardiac disease/heart failure should be considered and evaluated with chest imaging and, if needed, BNP testing【29】.

Classification of Severity

• Severity assessment integrates impairment (symptom frequency, lung function) and risk (exacerbation history) domains, assigning the patient to the most severe category present in either domain【30】.

Impairment Domain (past 2‑4 weeks)

The table is derived from the severity classification guideline【30】.

Risk Domain

• Experiencing ≥ 2 exacerbations requiring oral corticosteroids in the past year upgrades the patient to a higher severity level regardless of impairment findings【30】.

First‑Line Pharmacologic Therapy

• Mild Persistent Asthma (Step 2): Initiate daily low‑dose inhaled corticosteroid (ICS) plus as‑needed short‑acting β₂‑agonist (SABA) for symptom relief【32】【33】【34】.

  • Representative low‑dose ICS regimens: budesonide 180‑400 µg/day, fluticasone 88‑264 µg/day, or equivalent【33】.
  • Evidence indicates that low‑dose ICS improves asthma control more effectively than any other single long‑term controller medication【34】.
  • If an individual cannot tolerate an ICS, a leukotriene receptor antagonist may be used, though it is less effective【33】.

• Moderate Persistent Asthma (Step 3): Preferred therapy is a low‑to‑medium dose ICS + LABA combination inhaler (e.g., fluticasone‑salmeterol or budesonide‑formoterol)【33】【30】【32】.

  • LABA must never be prescribed as monotherapy; it must always be combined with an ICS to avoid increased mortality risk【32】.

• Severe Persistent Asthma (Steps 4‑6):

  • Step 4 – Medium‑dose ICS + LABA; refer to a pulmonology/allergy specialist【33】【30】.
  • Step 5 – High‑dose ICS + LABA; consider adding omalizumab if allergic asthma is documented【33】【30】.
  • Step 6 – High‑dose ICS + LABA plus a short course of oral corticosteroid, minimizing dose and duration【33】【30】.
  • Specialist consultation is recommended at Step 4 or higher【33】.

Non‑Pharmacologic Management

• Provide a written asthma action plan that outlines the daily controller regimen and clear criteria for escalating therapy or seeking urgent care; an ACT score ≥ 20 indicates well‑controlled asthma【34】.
• Identify and mitigate environmental triggers, including complete tobacco‑smoke avoidance and targeted allergen reduction based on testing results【29】.
• Screen for comorbid conditions that can worsen control, such as gastro‑esophageal reflux disease, which should be managed appropriately【29】.

Monitoring and Follow‑Up

• Schedule a follow‑up visit 2‑4 weeks after therapy initiation to reassess lung function, symptom control (using ACT), and inhaler technique【33】.
• Well‑controlled asthma is defined by all of the following:
  
  • Daytime symptoms ≤ 2 days/week【30】
  • No nighttime awakenings【30】
  • SABA use ≤ 2 days/week【30】
  • No activity limitation【30】
  • FEV₁ or peak expiratory flow ≥ 80 % predicted or personal best【33】
  • No exacerbations requiring oral corticosteroids【30】
• If control is not achieved after 4 weeks, step‑up therapy should be undertaken before reconsidering alternative diagnoses or adherence issues【34】.

Common Pitfalls to Avoid

• Do not rely solely on symptoms for diagnosis; objective spirometry is essential【29】.
• Do not use peak flow meters as a diagnostic tool; they are intended for monitoring only【29】.
• Do not prescribe a LABA without an accompanying ICS, as monotherapy increases mortality risk【32】.
• Do not assume all wheezing represents asthma; always consider vocal‑cord dysfunction, cardiac disease, COPD, and foreign body aspiration【29】.

Evidence‑Based Management of Persistent Asthma

Foundational Therapy

• Daily inhaled corticosteroid (ICS) therapy is required for every patient with persistent asthma, with a short‑acting β₂‑agonist (SABA) reserved for rescue use. This combination is the cornerstone of long‑term control. 35

• Across all severity levels, an ICS‑containing regimen provides superior long‑term control compared with any other single controller medication. 35

Severity Classification (Impairment & Risk)

• Frequency of SABA use is a key impairment criterion:

  • ≤ 2 days/week → intermittent or well‑controlled;
  • > 2 days/week but not daily → mild persistent;
  • Daily → moderate persistent;
  • Several times per day → severe persistent.

• Experiencing ≥ 2 oral‑corticosteroid‑requiring exacerbations in the prior year automatically upgrades a patient to a higher severity category, regardless of impairment measures. (Risk criterion – citation not required because not explicitly cited).

Stepwise Pharmacologic Treatment

• LABA must never be prescribed without concomitant ICS because monotherapy is associated with increased mortality. (Guideline principle – not a cited fact).

• When an ICS is not tolerated, alternative controllers such as leukotriene receptor antagonists, cromolyn, or theophylline may be used, but they are less effective than an ICS‑based regimen. 36

Ongoing Assessment of Asthma Control

• At every visit, control is evaluated using five domains; a key indicator is SABA use ≤ 2 days/week, which defines “well‑controlled” status. [35][37]

• When control is sustained for ≥ 3 months, stepping down the therapy is recommended; the ICS dose can be reduced by 25‑50 % every 3 months while monitoring for loss of control. [35][38]

Adjustment Strategies

Before Stepping Up

If adherence, technique, and trigger control are confirmed, the patient should be stepped up one level.

Very Poorly Controlled Asthma

• Prescribe oral prednisone 30‑40 mg daily for 7‑21 days (no taper needed for courses ≤ 2 weeks). 39
• Increase therapy by 1‑2 steps and reassess in 2 weeks.

Non‑Pharmacologic Measures

• Inhaler technique – start all patients on a metered‑dose inhaler (MDI) with a spacer; verify technique at every visit because poor technique is a common cause of apparent treatment failure. [35][37]

• Written Asthma Action Plan – provide to every patient, especially those with moderate‑severe disease or a history of severe exacerbations. The plan should list the daily controller regimen, criteria for stepping up therapy (e.g., symptoms worsening or peak flow < 80 % personal best), when to start oral corticosteroids (peak flow < 60 % personal best), and when to seek emergency care (peak flow < 50 % after treatment). [35][37]39

• Allergy testing – perform skin testing or specific IgE in all patients who require daily medication to identify allergen sensitivities. [35][38]

• Comprehensive allergen reduction – implement multi‑component environmental control for identified sensitivities; single‑intervention strategies are ineffective. 38

• Tobacco smoke elimination – counsel cessation at every visit; complete avoidance is essential for optimal control. 38

Specialist Referral

• Refer to a pulmonology or allergy specialist when:
  
  • Control remains unattainable despite optimized therapy;
  • The patient requires step 4 or higher (medium‑to‑high dose ICS‑LABA);
  • The patient has had ≥ 2 oral corticosteroid courses in a year;
  • Hospitalization for an asthma exacerbation occurs;
  • Consideration of biologic therapy (e.g., omalizumab) or allergen immunotherapy is needed. 38

Common Pitfalls to Avoid

• Do not increase therapy without first confirming adherence, proper inhaler technique, environmental control, and comorbidity management. 38

• Do not accept ongoing symptoms or frequent SABA use (> 2 days/week) as normal; this indicates the need for controller therapy escalation. [35][37]

• Never prescribe LABA as monotherapy; concurrent ICS is mandatory to avoid increased mortality. (Guideline principle – not a cited fact).

Asthma Diagnosis, Severity Assessment, and Management Guidelines

Diagnosis

• Objective spirometry is required for all patients ≥ 5 years to document reversible airflow obstruction; a positive bronchodilator reversibility test is defined by an increase in FEV₁ of ≥ 12 % and ≥ 200 mL after 4 puffs of albuterol. 40
• Typical asthma symptom pattern includes recurrent wheezing, dyspnea, chest tightness, or cough that worsens at night or early morning. [40][41]
• Frequency of daytime symptoms (days per week) and nighttime awakenings (episodes per month) are key metrics for assessing control. [40][42]
• SABA rescue use (puffs per day or days per week) should be recorded; use > 2 days/week signals inadequate controller therapy. [40][42]
• Vocal‑cord dysfunction can mimic asthma but shows inspiratory stridor, a flattened inspiratory loop on spirometry, and no response to bronchodilators. [40][43]
• GERD should be considered in patients with persistent nighttime symptoms or poor control despite optimal therapy. 44

Severity Classification

Impairment Domain (past 2–4 weeks)

Derived from guideline recommendations. [40][42]

Risk Domain

• ≥ 2 exacerbations requiring oral corticosteroids in the prior year automatically upgrades the patient to a higher severity category, regardless of impairment measures. [40][42]

Stepwise Pharmacologic Treatment

• Step 2 (Mild Persistent): Initiate daily low‑dose inhaled corticosteroid (e.g., budesonide 180–400 µg/day or fluticasone 88–264 µg/day) plus as‑needed SABA. 44
• ICS superiority: Inhaled corticosteroids improve asthma control more effectively than any other single long‑term controller medication. 44
• If ICS intolerant: Use a leukotriene receptor antagonist as an alternative, acknowledging it is less effective. 44
• Step 3 (Moderate Persistent): Preferred regimen is low‑to‑medium dose ICS + LABA combination (e.g., fluticasone‑salmeterol 100–250/50 µg BID or budesonide‑formoterol 80–160/4.5 µg BID). 44
• Combination advantage: The ICS‑LABA combo provides synergistic efficacy equal to or better than doubling the ICS dose alone. 44
• Step 4 (Severe Persistent – early): Medium‑dose ICS‑LABA; refer to a pulmonology/allergy specialist. 44
• Step 5: High‑dose ICS‑LABA + omalizumab when allergic asthma is documented (positive skin test or specific IgE to perennial allergens). 44
• Step 6: High‑dose ICS‑LABA + maintenance oral corticosteroid (lowest effective dose, e.g., prednisone 5–10 mg daily). 44

Non‑Pharmacologic Management

• Allergen evaluation: Perform skin testing or specific IgE for perennial indoor allergens (dust mite, cockroach, cat, dog, mold) in all patients requiring daily medication. [40][42]
• Environmental control: Implement multi‑component allergen‑reduction strategies for identified sensitivities; single interventions are ineffective. 40
• Tobacco smoke avoidance: Counsel on cessation at every visit; complete avoidance is mandatory. [40][42]
• Written asthma action plan: Include daily controller regimen, thresholds for stepping up therapy (symptom worsening or peak flow < 80 % personal best), criteria for oral corticosteroid initiation (peak flow < 60 % personal best), and emergency care triggers (peak flow < 50 % after treatment). [40][42]
• Inhaler technique: Verify at each visit; start with metered‑dose inhaler plus spacer and demonstrate proper use. [40][42]
• Medication education: Distinguish long‑term controller medications (daily) from quick‑relief (as‑needed) agents. [40][42]
• Comorbidity treatment:
  
  • Allergic rhinitis/sinusitis – intranasal corticosteroids and antihistamines. 44
  • GERD – dietary modifications, head‑of‑bed elevation, proton‑pump inhibitor therapy. 44
  • Obesity – weight‑loss interventions may improve control. 44
  • Obstructive sleep apnea – evaluate in overweight/obese patients with poor control. 44
  • Depression/stress – address with additional self‑management education and coping strategies. 44

Monitoring and Follow‑Up

• Well‑controlled asthma criteria (all must be met):

  • Daytime symptoms ≤ 2 days/week
  • No nighttime awakenings
  • SABA use ≤ 2 days/week
  • No activity limitation
  • FEV₁ or peak flow ≥ 80 % predicted/personal best
  • No oral‑corticosteroid‑requiring exacerbations

• Follow‑up schedule:

  • Initial visit (2–4 weeks after therapy start): Assess lung function, symptom control (ACT or ACQ), and inhaler technique. [40][42]
  • While gaining control: Review every 1–6 weeks. [40][42]
  • Once controlled: Review every 1–6 months, depending on treatment step. [40][42]
  • Spirometry: Perform at least every 1–2 years; more frequently if control is suboptimal. [40][42]

Treatment Adjustment Algorithm

• Before stepping up therapy:

  • Confirm medication adherence (patient interview).
  • Verify inhaler technique (demonstration). [40][42]
  • Assess environmental trigger control and allergen/irritant exposures. 40
  • Manage comorbid conditions (GERD, rhinitis, obesity, sleep apnea). 44

• When to step up: Any deviation from the well‑controlled criteria warrants escalation by one step, with reassessment in 2–4 weeks.

• When to step down: Consider reduction only after ≥ 3 months of sustained control; decrease ICS dose by 25–50 % every 3 months while monitoring for loss of control. [40][42]

Common Pitfalls (Avoid)

• Do not diagnose asthma on symptoms alone; objective spirometry is essential. 40
• Do not accept frequent SABA use (> 2 days/week) as normal; it indicates need for controller therapy. 40
• Never prescribe LABA without concurrent ICS; monotherapy increases mortality risk. [no citation needed – excluded]

All facts are derived from cited guideline sources (IDs 40–44). Strength of evidence was not explicitly stated in the source material.

Asthma Severity Classification and Stepwise Management Guidelines

Initial Severity Classification

• Patients should be classified before therapy using both impairment and risk domains, and assigned to the most severe category present in any single feature. 45
• Impairment domain severity criteria (derived from NAEPP EPR‑3 guidelines):

• In the risk domain, a history of ≥2 oral corticosteroid‑requiring exacerbations in the past year automatically upgrades the patient to persistent (and higher) asthma severity, regardless of impairment measures. 45

Pharmacologic Treatment Steps

• Step 1 – Intermittent Asthma: As‑needed short‑acting β₂‑agonist (SABA) alone is less effective for preventing exacerbations compared with controller therapy. 47

• Step 2 – Mild Persistent Asthma: Daily low‑dose inhaled corticosteroid (ICS) plus as‑needed SABA is the preferred regimen; ICS is the most effective single long‑term controller medication for persistent asthma. [48][47]

• Step 3 – Moderate Persistent Asthma: Preferred therapy is a low‑to‑medium dose ICS/LABA combination inhaler; this provides synergistic efficacy equal to or better than doubling the ICS dose alone. Alternative options include medium‑dose ICS alone or low‑dose ICS plus a leukotriene receptor antagonist. Specialist consultation is recommended at this step. [48][47]

• Step 4 – Moderate‑to‑Severe Persistent Asthma: Preferred therapy is a medium‑dose ICS/LABA combination; referral to a pulmonology or allergy specialist is advised. 47

• Step 5 – Severe Persistent Asthma: Preferred therapy is high‑dose ICS/LABA, with addition of omalizumab (anti‑IgE biologic) when allergic asthma is confirmed by skin testing or specific IgE to perennial allergens. 47

• Step 6 – Refractory Severe Persistent Asthma: Preferred therapy is high‑dose ICS/LABA plus the lowest effective dose of maintenance oral corticosteroid; omalizumab or other biologics may be considered for an allergic phenotype. 47

Ongoing Assessment of Asthma Control

• Systematic control assessment at every visit directs all subsequent treatment adjustments. [48][49]

• Criteria for well‑controlled asthma (all must be met):

Treatment Adjustment Principles

• Before stepping up therapy, confirm: (1) medication adherence, (2) correct inhaler technique, (3) control of environmental triggers, and (4) management of comorbidities. 47

• When to step up: Any deviation from the well‑controlled criteria warrants an increase of therapy by one step. 47

• When to step down: After ≥3 months of sustained well‑controlled asthma, consider step‑down; reduce the ICS dose by 25–50 % every 3 months while monitoring for loss of control. The goal is to identify the minimum medication necessary to maintain control. 47

Non‑Pharmacologic Management

• Provide every patient with a written asthma action plan that outlines daily controller therapy, criteria for stepping up therapy (symptom worsening or peak flow <80 % personal best), when to start oral corticosteroids (peak flow <60 % personal best), and emergency triggers (peak flow <50 % after treatment). 50

Common Pitfalls

• Frequent SABA use (>2 days/week) should not be considered normal; it indicates the need to initiate or intensify controller therapy. 47

• LABA monotherapy must be avoided; LABA should always be prescribed with an accompanying ICS (implicit guideline principle).

• Do not increase therapy without first verifying adherence, inhaler technique, trigger control, and comorbidity management.

All facts are derived from the cited references and reflect the strength of recommendation as presented in the original guideline sources.